Relationship Between Expression of Coactivators and Corepressors of Hormone Receptors and Resistance of Ovarian Cancers to Growth Regulation by Steroid Hormones
Restricted accessResearch articleFirst published online March, 2001
Relationship Between Expression of Coactivators and Corepressors of Hormone Receptors and Resistance of Ovarian Cancers to Growth Regulation by Steroid Hormones
OBJECTIVE: To determine whether aberrant expression of hormone receptor corepressors or coactivators or defects in estrogen receptor—mediated transcription might underlie resistance of ovarian cancers to hormonal therapy.
METHODS: Northern analysis, Western analysis, and polymerase chain reaction were used to examine expression of estrogen receptor (ER), progesterone receptor (PR), the nuclear receptor corepressors N-CoR and SMRT, and the steroid receptor coactivator BRG-1 in ovarian cancer cell lines and primary cancers. The effect of BRG-1 transfection on ER-mediated transcription was examined. We also determined the effect of estrogen and the pure estrogen antagonist ICI 182, 780 on cell cycle profile and expression of ER. Finally, we examined the ability of estrogen to upregulate expression of known estrogen-responsive genes.
RESULTS: Among primary ovarian cancers, 18 of 52 (35%) expressed N-CoR, and 37 of 52 (71%) expressed SMRT, but there was no correlation between expression of corepressors and hormone receptor status. All of the primary ovarian cancers and cell lines expressed BRG-1. Estrogen stimulation of two cell lines expressing ER (SKOV3, OVCA 432) elicited low levels of ER-mediated transcription that was not enhanced by BRG-1 transfection. ICI 182, 780 did not induce cell cycle arrest in these cell lines, but there was evidence of downregulation of ER, indicating a ligand-receptor interaction. However, estrogen did not elicit increased transcription of estrogen-responsive genes (PR, myc, fos, pS2).
CONCLUSION: Inappropriate expression of the nuclear corepressors N-CoR and SMRT or the coactivator BRG-1 does not underlie the resistance of ovarian cancers to hormonal therapy. Further studies are needed to elucidate the mechanisms underlying the inability of ovarian cancers to undergo ER-mediated transcription if we hope to understand their resistance to hormonal therapy.
1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared With pacitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med1996;334: 1-6.
2.
2. Masood S, Heitmnann J, Nuss RC, Benrubi GI. Cliiical correlation of hormone receptor status in epithelial ovarian cancer. Gynecol Oncol1989;34:57-60.
3.
3. Schwartz PE, Memno VlJ, Livolsi VA, Lawrence R. MacLusky N, Eisenfeld A. Histopathologic correlations of estrogen and progestin receptor protein in epithelial ovarian carcinomas. Obstet Gynecol1985;66:428-433.
4.
4. Geisler HE. The use of high-dose megestrol acetate in the treatment of ovarian adenocarcinoma. Semin Oncol1985;12: 20-22.
5.
5. Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clii Oncol1983;1:227-241.
6.
6. Pichon MF, Pallud C, Brunet M, Milgrom E. Relationship of presence of progesterone receptors to proglosis in early breast cancer. Cancer Res1980;40:3357-3360.
7.
7. Jensen EV. Hormone dependency of breast cancer. Cancer1976;47:2319-2326.
8.
8. Knight WA, Livingston RB, Gregory EJ, McGuire WL. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res1977;37:4669-4671
9.
9. Creasman WT, Soper JT, McCarty KS Jr, McCarty JS Sr, Hinshaw W, Clarke-Pearson DL. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol1985;151:922-932.
10.
10. Benraad TJ, Friberg LG, Koenders AJ, Kullander S. Do estrogen and progesterone receptors (E2R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy?Acta Obstet Gynecol Scand1980;59:155-159.
11.
11. Martin PM, Rolland PH, Gammerre M, Serment H, Toga M. Estradiol and progesterone receptors in normal and neoplastic endometrium: Correlations between receptors, histopathological examinations and clinical responses under progestin therapy. Int J Cancer1979;23:321-329.
12.
12. Ehrlich CE, Young PC, Cleary RE. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: Therapeutic implications. Am J Obstet Gynecol1981;141:539-546.
13.
13. Slotman BJ, Kuhnel R, Rao BR, Dijkhuizen GH, de Graaff J, Stolk JG. Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: High tumor progesterone receptor levels correlate with longer survival. Gynecol Oncol1989;33:76-81.
14.
14. Schwartz PE, MacLusky N, Merino MJ, Livolsi VA, Kohorn El, Eisenfeld A. Are cytosol estrogen and progestin receptors of prognostic significance in the management of epithelial ovarian cancers?Obstet Gynecol1986;68:751-758.
15.
15. Sevelda P, Denison U, Schemper M, Spona J, Vavra N, Salzer H. Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma. Br J Obstet Gynaecol1990;97:706-712.
16.
16. Ahlgren JD, Ellison NM, Gottlieb RJ, et al. Hormonal palliation of chemoresistant ovarian cancer: Three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol1993; 11:1957-1968.
17.
17. Belinson JL, Mc Clure M, Badger G. Randomized trial of megestrol acetate vs. megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma. Gynecol Oncol1987;28:151-155.
18.
18. Sikic BI, Scudder SA, Ballon SC, et al. High-dose megestrol acetate therapy of ovarian carcinoma: A phase II study by the Northern California Oncology Group. Semin Oncol1986;13: 26-32.
19.
19. van der Vange N, Greggi S, Burger CW, Kenemans P, Vermorken JB. Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol1995;34:813-820.
20.
20. Veenhof CH, van der Burg ME, Nooy M, et al. Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. Eur J Cancer1994;30A:697-698.
21.
21. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol1997;11:657-666.
22.
22. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol1997;11:693-705.
23.
23. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP. The nuclear corepressors N-CoR and SMRT are key regulators of both ligand and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol1998;18:1369-1378.
24.
24. Ichinose H, Garnier JM, Chambon P, Losson R. Ligand-dependent interaction between the estrogen receptor and the human homologues of SWI2/SNF2. Gene1997;188:95-100.
25.
25. Chiba H, Muramatsu M, Nomoto A, Kato H. Two human homologues of Saccharomyces cerevisiae SW12/SNF2 and Drosophila brahma are transcriptional coactivators cooperating with the estrogen receptor and the retinoic acid receptor. Nucleic Acids Res1994;22:1815-1820.
26.
26. Bast RCJ, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest1981;68:1331-1337.
27.
27. Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast RC Jr. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol1991;164:745-750.
28.
28. Kumar NS, Richer J, Owen G, Litman E, Horwitz KB, Leslie KK. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: Implications for unopposed estrogen action. Cancer Res1998;58: 1860-1865.
29.
29. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and mahgnant ovarian epithelial cells. Proc Natl Acad Sci U S A1999;96:5722-5727.
30.
30. Kauppila A, Vierikko P, Kivinen S, Stenback F, Vihko R. Clinical significance of estrogen and progestin receptors in ovarian cancer. Obstet Gynecol1983;61:320-326.
31.
31. Harding M, Cowan S, Hole D, et al. Estrogen and progesterone receptors in ovarian cancer. Cancer1990;65:486-491.
32.
32. Rose PG, Reale FR, Longcope C, Hunter RE. Prognostic significance of estrogen and progesterone receptors in epithelial ovanan cancer. Obstet Gynecol1990;76:258-263.
34. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Du Beshter B. Tamoxifen in platinum-refractory ovarian cancer: A Gynecologic Oncology Group Ancillary Report. Gynecol Oncol1996;62:4-6.
35.
35. Slevin ML, Harvey VJ, Osborne RJ, Shepherd JH, Williams CJ, Mead GM. A phase II study of tamoxifen in ovarian cancer. Eur J Cancer Clin Oncol1986;22:309-312.
36.
36. Quinn, MA, Rome, RM, Grant P, Planner RS. High dose medroxyprogesterone acetate in advanced ovarian cancer. Int J Gynecol Cancer1991;1:239-241.
37.
37. MalfetanoJ, Beecham JB, Bundy BN, Hatch KD. A phase II trial of medroxyprogesterone acetate in epithelial ovarian cancers. A Gynecologic Oncology Group study. Am J Clin Oncol1993;16: 149-151.
38.
38. Wiernik PH, Greenwald ES, Ball H, Young JA, Vogl S. Highdose megestrol acetate in the treatment of patients with ovarian cancer who have undergone previous treatment: Eastern Cooperative Oncology Group Study PD884. Am J Clin Oncol1998; 21:565-567.
39.
39. Tonetti DA, Jordan VC. The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. J Steroid Biochem1997; 62:119-128.
40.
40. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A1996;93:5925-5930.
42. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology1999; 140:5566-5578.
43.
43. Pujol P, Rey JM, Nirde P, et al. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res1998;58:5367-5373.
44.
44. Leach RE, Duniec ZM, Khalifa RAG, Rameriz ND, Diamond MP. Progesterone receptor A and B isoforms across the human menstrual cycle. J Soc Gynecol Investig1997;4:125A-125A.
45.
45. Graham JD, Yeates C, Balleine RL, et al. Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res1995;55:5063-5068.
46.
46. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP. Human progesterone receptor A form is a cell and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol1993;7:1244-1255.
47.
47. Csernus VJ, Schally AV, Kiaris H, Armatis P. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci U S A1999;96:3098-103.
48.
48. Morishige K, Kurachi H, Amemiya K, et al. Involvement of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vitro. Cancer Res1991;51:5951-5955.
49.
49. Vaughn JP, Davis PL, Jarboe MD, et al. BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ1996;7:711-715.
50.
50. Hua W, Christianson T, Rougeot C, Rochefort H, Clinton GM. SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. J Steroid Biochem Mol Biol1995;55:279-289.
51.
51. Langdon SP, Hirst GL, Miller EP, et al. The regulation of growth and protein expression by estrogen in vitro: A study of 8 human ovarian carcinoma cell hnes. J Steroid Biochem Mol Biol1994; 50:131-135.
52.
52. Sutherland RL, Hall RE, Taylor IW. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res1983;43:3998-4006.
53.
53. Sutherland RL, Green MD, Hall RE, Reddel RR, Taylor IW. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/Gl phase of the cell cycle. Eur J Cancer Clin Oncol1983;19:615-621.
54.
54. Parker MG, Arbuckle N, Dauvois S, Danielian P, White R. Structure and function of the estrogen receptor. Ann N Y Acad Sci1993;684:119-126.
55.
55. Dubik D, Dembinski TC, Shiu RP. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res1987;47:6517-6521.
56.
56. Wilding G, Lippman ME, Gelmann EP. Effects of steroid hormones and peptide growth factors on protooncogene c-fos expression in human breast cancer cells. Cancer Res1988;48: 802-805.
57.
57. Dubik D, Shiu RP. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene1992;7:1587-1594.
58.
58. Weisz A, Rosales R. Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. Nucleic Acids Res1990;18:5097-106.
59.
59. May FE, Westley BR. Cloning of estrogen-regulated messenger RNA sequences from human breast cancer cells. Cancer Res1986;46:6034-6040.
60.
60. Jakowlew SB,Breathnach R, Jeltsch JM, Masiakowski P, Chambon P. Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res1984; 12:2861-2878.
61.
61. Horwitz KB, McGuire WL. Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J Biol Chem1978;253: 8185-8191.
62.
62. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem1978;253:2223-2228.
